secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2026-05-12T10:45:26+00:00
Accession:  0001104659-26-058967
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences Q1 net loss $8.2M; PRECISE-AD interim analysis expected early Q3 2026
--------------------------------------------------------------------------------

- Net loss of $8.2M for Q1 2026, vs $7.3M in Q1 2025; cash & equivalents $63.8M as of March 31.
- Closed $75.5M PIPE in Feb 2026; up to $100M additional from warrant exercises; funds operations through 2027.
- PRECISE-AD Phase 1b fully enrolled (144 participants); blinded 6-month interim analysis anticipated early Q3 2026.
- Unblinded 12-month top-line data expected early 2027; subcutaneous formulation development accelerated.
- Lead candidate PMN310 selectively targets toxic amyloid-beta oligomers, aiming to improve safety vs plaque-directed antibodies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/0001104659-26-058967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-058967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer